Cabot (NYSE:CBT) and Artemis Therapeutics (OTCMKTS:ATMS) are both basic materials companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.
Insider and Institutional Ownership
86.4% of Cabot shares are owned by institutional investors. 2.2% of Cabot shares are owned by company insiders. Comparatively, 7.5% of Artemis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Cabot has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cabot and Artemis Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cabot||$3.24 billion||0.84||-$113.00 million||$4.03||11.23|
|Artemis Therapeutics||N/A||N/A||-$1.14 million||N/A||N/A|
Artemis Therapeutics has lower revenue, but higher earnings than Cabot.
This is a summary of recent recommendations for Cabot and Artemis Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cabot currently has a consensus target price of $76.00, indicating a potential upside of 67.96%. Given Cabot’s higher possible upside, equities research analysts clearly believe Cabot is more favorable than Artemis Therapeutics.
This table compares Cabot and Artemis Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cabot pays an annual dividend of $1.32 per share and has a dividend yield of 2.9%. Artemis Therapeutics does not pay a dividend. Cabot pays out 32.8% of its earnings in the form of a dividend. Cabot has raised its dividend for 7 consecutive years.
Cabot beats Artemis Therapeutics on 9 of the 13 factors compared between the two stocks.
Cabot Corporation operates as a specialty chemicals and performance materials company. The company offers rubber grade carbon blacks used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and compounds of carbon black and rubber. It also provides specialty grades of carbon black used in inks, coatings, plastics, adhesives, toners, batteries, and displays applications; masterbatch and conductive compound products for use in automotive, industrial, packaging, consumer products, and electronics industries; inkjet colorants used in the inkjet printing applications; fumed silica used in adhesives, sealants, cosmetics, batteries, inks, toners, silicone elastomers, coatings, polishing slurries, and pharmaceuticals; fumed alumina used in various products, including inkjet media, lighting, coatings, cosmetics, and polishing slurries; and aerogel, a hydrophobic, silica-based particle for use in various thermal insulation and specialty chemical applications. In addition, the company offers activated carbon products used for the purification of water, air, food and beverages, pharmaceuticals, and other liquids and gases; and activated carbon solutions for activated carbon injection in coal-fired utilities, mobile water filter units, and carbon reactivation services. Further, it provides cesium formate brines used as a drilling and completion fluid primarily in high pressure and high temperature oil and gas well construction; and fine cesium chemicals used in a range of industries and applications that include catalysts, doping agents, and brazing fluxes. The company sells its products primarily through distributors and sales representatives in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Cabot Corporation was founded in 1882 and is headquartered in Boston, Massachusetts.
About Artemis Therapeutics
Artemis Therapeutics Inc., a biopharmaceutical company, engages in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company's lead product candidate is Artemisone, an orally-administered 10-alpha-amino artemisinin derivative with antiviral and antiparasitic properties. It focuses on advancing Artemisone as an antiparasitic treatment for patients infected with Plasmodium falciparum; and as an antiviral agent to address unmet clinical needs in immunocompromised patients infected with human cytomegalovirus and other viral or infectious diseases. The company has license agreement with Hadasit Medical Research Services and Development Ltd., Hadassah Medical Organization, and Hong Kong University of Science and Technology R and D Corporation Limited for the development of Artemisone. Artemis Therapeutics Inc. was incorporated in 1997 and is based in New York, New York. Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.
Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.